$0.24
-0.02 (-6.92%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VTGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 4 with posted results
Held by 4 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC) · FINRA short interest 2.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety DisorderNCT06809179Subjective Units of Distress Scale (SUDS)Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray | Social Anxiety Disorder | 60 | Apr 2026 | 2026-02-05 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)NCT06615557Subjective Units of Distress Scale (SUDS)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Fasedienol Nasal Spray, Placebo Nasal Spray | Social Anxiety Disorder (SAD) | 238 | 2026-04-21actual | 2026-05-22 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)NCT06358651Subjective Units of Distress Scale (SUDS)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Fasedienol Nasal Spray, Placebo Nasal Spray | Social Anxiety Disorder | 238 | 2025-10-31actual | 2025-11-26 |
| AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaNCT04147949Unified Dyskinesia Rating ScaleRandomized · Double-masked · Treatment | Phase 2 | Unknown status | Drug: AV-101, Placebo | Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use | 20 | Dec 2023 | 2021-05-26 |
| PH94B in the Treatment of Adjustment Disorder With AnxietyNCT04404192results2026-02-05Hamilton Anxiety Scale (HAM-A) ScoreRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PH94B, Placebo | Adjustment Disorder With Anxious Mood | 41 | 2022-12-14actual | 2026-02-05 |
| Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)NCT05030350results2025-10-21Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study stopped by the sponsor for business reasons and not due to any safety concerns with PH94B | Drug: PH94B | Social Anxiety Disorder | 481 | 2022-09-23actual | 2025-10-21 |
| AV-101 Alone and in Combination With Probenecid in Healthy SubjectsNCT05280054Plasma and CSF concentrations of 7-chloro-kynurenic acid (7-Cl-KYNA) in ng/mlNon-randomized · Open-label · Basic science | Phase 1 | Unknown status | Drug: AV-101, Probenecid | Drug Drug Interaction | 24 | 2022-09-01 | 2022-03-15 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2NCT05011396results2025-11-24Subjective Units of Distress Scale (SUDS)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study stopped by the sponsor for business reasons and not due to any safety concerns with PH94B | Drug: PH94B Nasal Spray, Placebo Nasal Spray | Social Anxiety Disorder | 228 | 2022-08-16actual | 2025-11-24 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking ChallengeNCT04754802results2025-09-12Subjective Units of Distress Scale (SUDS) ScoreRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: PH94B Nasal Spray, Placebo Nasal Spray | Social Anxiety Disorder | 224 | 2022-06-22actual | 2025-09-12 |
| AV-101 as Adjunct Antidepressant Therapy in Patients With Major DepressionNCT03078322Montgomery Åsberg Depression Rating Scale 10-item version (MADRS-10)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AV-101, Placebo | Major Depressive Disorder | 180 | 2019-10-01actual | 2019-10-09 |
| Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy VolunteersNCT01483846PharmacokineticsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AV-101, Placebo | Neuropathic Pain | 50 | Sep 2012actual | 2012-12-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19